Vasculitis & polymyalgia rheumatica
Efficacy and safety of tofacitinib in polymyalgia rheumatica: a retrospective comparative study
Authors' conclusion
Tofacitinib-containing regimens were associated with improvement in PMR disease activity, and combination treatment was associated with lower prednisone exposure.
Study context
- Population
- Patients diagnosed with polymyalgia rheumatica (PMR) between February 2021 and March 2025, single centre
- Participants
- 60 patients
- Exposure
- Tofacitinib monotherapy vs tofacitinib plus prednisone vs prednisone monotherapy
- Tofacitinib monotherapyn = 14
- Tofacitinib + prednisonen = 20
- Prednisone monotherapyn = 26reference
- Outcome
- Change in PMR-AS from baseline to month 6
- Follow-up
- Month 6
Methodological detailssingle-centre, comparative
- Single-centre
- Comparative
Main finding
As reported in the abstract
Mean change in PMR-AS · 6 months
- Significant within-group improvement in Polymyalgia Rheumatica Activity Score (PMR-AS) with all regimens
- p < 0.01
Observational data: associations, not effects.
Secondary outcomes
Other outcomes (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), visual analogue scales (VAS), haemoglobin, platelet (PLT), morning stiffness) · 6 months
- Significant within-group improvements with all regimens
- P < 0.01 for all
- Mean changes did not differ significantly among groups
Daily and cumulative prednisone dose
- Lower daily and cumulative prednisone doses with tofacitinib + prednisone
- P < 0.01
Safety
Serious adverse events · 6 month follow-up
- No serious adverse events recorded
Original publication
Efficacy and safety of tofacitinib in polymyalgia rheumatica: a retrospective comparative study. Scand J Rheumatol. Published 16 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →